Plus Therapeutics Inc (PSTV)

Jan 07, 2026

How Plus Therapeutics Inc. stock reacts to job market dataSector Performance Drivers & Minimal Capital Trading - ulpravda.ru

Jan 07, 2026

Jan 07, 2026

Can Plus Therapeutics Inc. stock continue upward trendStock Rotation Strategies & Outstanding Wealth Building - ulpravda.ru

Jan 07, 2026

Jan 06, 2026

2026 world cup points table rankings: How Plus Therapeutics Inc. stock responds to policy changes2026 world cup usa national team round of 32 star players set piece tactics knockout prediction tactical review - ulpravda.ru

Jan 06, 2026

Jan 04, 2026

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN

Jan 04, 2026

Jan 01, 2026

Analyst Downgrade: How Plus Therapeutics Inc XMP0 stock expands through international marketsMarket Risk Summary & Accurate Intraday Trade Tips - moha.gov.vn

Jan 01, 2026

Jan 01, 2026

Guidance Update: Can Plus Therapeutics Inc XMP0 stock attract analyst upgradesJuly 2025 Setups & Safe Entry Momentum Tips - moha.gov.vn

Jan 01, 2026

Dec 21, 2025

Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Dec 21, 2025

Dec 21, 2025

How Plus Therapeutics Inc. stock responds to policy changes2025 Market Overview & Safe Entry Momentum Tips - ulpravda.ru

Dec 21, 2025

Dec 19, 2025

Is Plus Therapeutics Inc. (XMP0) stock a top hedge fund pick2025 Momentum Check & Real-Time Stock Price Movement Reports - Улправда

Dec 19, 2025

Dec 18, 2025

Can Plus Therapeutics Inc. (XMP0) stock ride next bull market cycleQuarterly Trade Summary & Weekly Breakout Stock Alerts - Улправда

Dec 18, 2025

Dec 17, 2025

Plus Therapeutics, Inc. (PSTV) Presents at 2025 San Antonio Breast Cancer Symposium (SABCS)Slideshow - Seeking Alpha

Dec 17, 2025

Dec 12, 2025

Plus Therapeutics (NASDAQ:PSTV) Earns "Buy" Rating from D. Boral Capital - MarketBeat

Dec 12, 2025

Dec 11, 2025

D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq

Dec 11, 2025

Dec 11, 2025

Analyst Jason Kolbert Maintains 'Buy' Rating for Plus Therapeuti - GuruFocus

Dec 11, 2025

Dec 11, 2025

CNSide Diagnostics expands lab licenses to three more states - Investing.com

Dec 11, 2025

Dec 11, 2025

Plus Therapeutics Expands CNSide Assay Platform to State of California - The Manila Times

Dec 11, 2025

Dec 09, 2025

Plus Therapeutics adds key personnel to CNSide Diagnostics team By Investing.com - Investing.com Canada

Dec 09, 2025

Dec 09, 2025

Plus Therapeutics (PSTV) Expands CNSide Diagnostics Team with Ke - GuruFocus

Dec 09, 2025

Dec 09, 2025

Plus Therapeutics adds key personnel to CNSide Diagnostics team - Investing.com

Dec 09, 2025

Dec 09, 2025

Plus Therapeutics Announces Key Hires to Strengthen Operations at CNSide Diagnostics, LLC - Quiver Quantitative

Dec 09, 2025

Dec 09, 2025

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants - The Manila Times

Dec 09, 2025

Dec 05, 2025

Why global investors buy Plus Therapeutics Inc. (XMP0) stockWeekly Investment Recap & Reliable Breakout Forecasts - Newser

Dec 05, 2025

Dec 04, 2025

Hines Adds 3 Life-Science Tenants at Levit Green - Realty News Report

Dec 04, 2025

Dec 04, 2025

Hines' Levit Green signs 3 biotech tenants for 30K-SF of lab and office space - The Business Journals

Dec 04, 2025

Dec 04, 2025

Plus Therapeutics Reports Positive Phase 1 Data for REYOBIQ in Leptomeningeal Metastases and Glioblastoma at WFNOS/SNO Annual Meeting | PSTV Stock News - Quiver Quantitative

Dec 04, 2025

Dec 04, 2025

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - The Manila Times

Dec 04, 2025

Dec 04, 2025

Will Plus Therapeutics Inc. (XMP0) stock rise with strong economyTrade Ideas & Precise Buy Zone Tips - Newser

Dec 04, 2025

Dec 03, 2025

How Plus Therapeutics Inc. stock reacts to Fed rate cutsIPO Watch & Technical Entry and Exit Tips - Newser

Dec 03, 2025

Dec 03, 2025

Will Plus Therapeutics Inc. (XMP0) stock beat Nasdaq index returns2025 Analyst Calls & Smart Allocation Stock Reports - Newser

Dec 03, 2025

Dec 02, 2025

Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital - MarketBeat

Dec 02, 2025

Dec 02, 2025

Aug Highlights: How Plus Therapeutics Inc. stock performs in weak economyMarket Sentiment Summary & Smart Allocation Stock Reports - BỘ NỘI VỤ

Dec 02, 2025

Dec 02, 2025

Will Plus Therapeutics Inc. stock gain from lower inflationTrade Signal Summary & High Accuracy Trade Alerts - Newser

Dec 02, 2025

Dec 02, 2025

How higher bond yields impact Plus Therapeutics Inc. (XMP0) stock2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser

Dec 02, 2025

Dec 02, 2025

How dovish Fed policy supports Plus Therapeutics Inc. (XMP0) stock2025 Price Action Summary & Risk Controlled Daily Trade Plans - Newser

Dec 02, 2025

Dec 02, 2025

Plus Therapeutics granted 180-day to regain compliance with Nasdaq - MSN

Dec 02, 2025

Dec 02, 2025

Why Plus Therapeutics Inc. stock is favored by top institutions - Newser

Dec 02, 2025

Dec 01, 2025

Plus Therapeutics (PSTV) Analyst Rating Update: Maintain Buy Rat - GuruFocus

Dec 01, 2025

Dec 01, 2025

Plus Therapeutics to present breast cancer treatment data at SABCS By Investing.com - Investing.com Nigeria

Dec 01, 2025

Dec 01, 2025

Plus Therapeutics to present breast cancer treatment data at SABCS - Investing.com

Dec 01, 2025

Dec 01, 2025

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - The Manila Times

Dec 01, 2025

Dec 01, 2025

Plus Therapeutics, Inc. Announces Abstract Acceptance for Spotlight Presentation at San Antonio Breast Cancer Symposium 2025 on Rhenium (186Re) obisbemeda for Leptomeningeal Metastases Treatment - Quiver Quantitative

Dec 01, 2025

Dec 01, 2025

Plus Therapeutics (NASDAQ: PSTV) lands SABCS 2025 spotlight for LM Phase 1 trial - Stock Titan

Dec 01, 2025